Skip to Content
Global News Select

Vera Therapeutics Buys Antibody for BK Virus From Pfizer

By Matt Grossman

 

Vera Therapeutics Inc. has acquired from Pfizer Inc. a monoclonal antibody aimed at treating BK virus, Vera said Friday.

The antibody, called MAU868, is in the middle of a Phase 2 clinical trial aimed at testing its safety and efficacy treating BKV in kidney-transplant patients. An interim analysis showed the drug to be well-tolerated with signs of efficacy, Vera said.

Most healthy adults have BK virus, but it remains latent in kidney and bladder tissue. It can become a problem with immune suppression and can cause clinical disease in transplant cases, according to Vera.

Oxford Finance LLC has provided a credit facility with borrowing capacity of up to $50 million to support the acquisition, Vera said.

 

Write to Matt Grossman at matt.grossman@wsj.com

 

(END) Dow Jones Newswires

December 17, 2021 08:05 ET (13:05 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.